United States was Azenta’s largest region in fiscal 2025, bringing in $365.00M of $593.82M (61%).
| Geography | FY 2009 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $358.21M | $365.05M | $365.00M | ||||||
| North America | — | — | — | ||||||
| Asia Pacific | $32.83M | $21.32M | $23.28M | ||||||
| Asia/Pacific | — | — | — | ||||||
| Rest Of Europe | — | — | — | ||||||
| Europe | $79.01M | $95.15M | $107.37M | ||||||
| China | $53.87M | $58.24M | $58.35M | ||||||
| Asia / Pacific / Other | — | — | — | ||||||
| United Kingdom | $30.26M | $27.20M | $35.39M | ||||||
| Other | — | $6.47M | $4.43M | ||||||
| Africa | $1.33M | — | — | ||||||
| Total | $555.50M | $573.45M | $593.82M |
Azenta brought in $593.82M from its six regions in fiscal 2025, the year ended September 30, 2025. That was up 3.6% from $573.45M in fiscal 2024. United States was the largest at $365.00M (61.5%), ahead of Europe at $107.37M (18.1%) and China at $58.35M (9.8%). The other three regions brought in $63.10M combined.
Compared with fiscal 2024, United Kingdom grew fastest, up 30.1% to $35.39M, while United States fell the most, down 0.0% to $365.00M.
Azenta began breaking out Other in fiscal 2024, when it brought in $6.47M. Azenta stopped reporting Africa as a separate region after fiscal 2022, when it brought in $1.33M.
Multiomics was Azenta’s largest segment in fiscal 2025, bringing in $269.23M of $593.82M (45%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2018 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brooks Product Solutions | — | — | — | — | |||||||||
| Brooks Semiconductor Solutions Group | — | — | — | — | |||||||||
| Life Sciences Services | — | — | — | — | |||||||||
| Sample Management Solutions | — | $303.19M | — | — | |||||||||
| Operating Segments, Total | — | — | — | — | |||||||||
| Multiomics | $250.94M | $248.30M | $254.55M | $269.23M | |||||||||
| Life Sciences Products | — | — | — | — | |||||||||
| Core Products | $199.23M | — | $196.50M | $197.63M | |||||||||
| Contract Manufacturing | — | — | — | — | |||||||||
| Sample Repository Solutions | $105.33M | $111.13M | $122.39M | $126.96M | |||||||||
| Brooks Life Sciences | — | — | — | — | |||||||||
| Brooks Life Science Systems | — | — | — | — | |||||||||
| Brooks Global Services | — | — | — | — | |||||||||
| Total | $555.50M | $662.62M | $573.45M | $593.82M |
Azenta brought in $593.82M from its three segments in fiscal 2025, the year ended September 30, 2025. That was up 3.6% from $573.45M in fiscal 2024. Multiomics was the largest at $269.23M (45.3%), ahead of Core Products at $197.63M (33.3%) and Sample Repository Solutions at $126.96M (21.4%).
Compared with fiscal 2024, Multiomics grew fastest, up 5.8% to $269.23M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $555.50M to $593.82M, a compound annual growth rate of 2.2%. Multiomics' share held steady at about 45.3%.
Azenta stopped reporting Sample Management Solutions as a separate segment after fiscal 2023, when it brought in $303.19M.
Service was Azenta’s largest product and service line in fiscal 2025, bringing in $420.63M of $593.82M (71%).
| Product and Service | FY 2018 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $374.55M | $98.02M | $391.67M | $295.87M | $399.98M | $103.68M | $410.14M | $309.70M | $420.63M | ||
| Services | — | — | — | — | — | — | — | — | — | ||
| Product | $180.95M | $43.71M | $82.48M | $126.51M | $173.72M | $43.83M | $85.78M | $125.17M | $173.19M | ||
| Products | — | — | — | — | — | — | — | — | — | ||
| Total | $555.50M | $141.73M | $474.15M | $422.37M | $573.70M | $147.51M | $495.92M | $434.87M | $593.82M |
Azenta brought in $593.82M from its two product and service lines in fiscal 2025, the year ended September 30, 2025. That was up 36.6% from $434.87M in fiscal 2025. Service was the largest at $420.63M (70.8%), ahead of Product at $173.19M (29.2%).
Compared with fiscal 2025, Product grew 38.4% to $173.19M and Service grew 35.8% to $420.63M. From fiscal 2022 to 2025, combined revenue from these lines grew from $555.50M to $593.82M, a compound annual growth rate of 2.2%. Service's share of the total rose from 67.4% to 70.8%.
Azenta (AZTA) reports its revenue by geography, by segment and by product and service. In fiscal 2025, United States was its largest region, bringing in $365.00M (61.5% of the total), followed by Europe at $107.37M (18.1%).
United States was Azenta's largest region in fiscal 2025, bringing in $365.00M, or 61.5% of the $593.82M total across its six regions.
Multiomics was Azenta's largest segment in fiscal 2025, bringing in $269.23M, or 45.3% of the $593.82M total across its three segments.
Service was Azenta's largest product and service line in fiscal 2025, bringing in $420.63M, or 70.8% of the $593.82M total across its two product and service lines.
Among Azenta's regions that make up at least 2% of revenue, United Kingdom grew fastest in fiscal 2025, up 30.1% from $27.20M to $35.39M.
Every figure comes from Azenta's annual financial filings, as reported. Each line keeps the name Azenta gives it, and years follow its fiscal calendar.
Azenta's revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.